| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| No Relationships to Disclose |
|
|
| Stock and Other Ownership Interests |
| No Relationships to Disclose |
|
|
| Honoraria |
| Company: CME Solutions |
| Recipient: You |
| Company: Janssen Pharmaceutical |
| Recipient: You |
| Company: MECC Global Meetings (CME) |
| Recipient: You |
| Company: Nanobiotix |
| Recipient: You |
| Company: Physician Education Resource (CME) |
| Recipient: You |
| Company: Jazz Pharmaceuticals |
| Recipient: You |
| Company: MOASC |
| Recipient: You |
| Company: MOASC |
| Recipient: You |
| Company: OncLive/MJH Life Sciences |
| Recipient: You |
| Company: Curio Science |
| Recipient: You |
| Company: New England Journal of Medicine |
| Recipient: You |
| Company: MJH Healthcare Holdings, LLC |
| Recipient: You |
| Company: PER CME |
| Recipient: You |
|
| Consulting or Advisory Role |
| Company: AstraZeneca |
| Recipient: You |
| Company: G1 Therapeutics |
| Recipient: You |
| Company: Blueprint Medicines |
| Recipient: You |
| Company: AstraZeneca (Steering Committee) |
| Recipient: You |
| Company: Genentech |
| Recipient: You |
| Company: Jazz Pharmaceuticals |
| Recipient: You |
| Company: Mirati Therapeutics |
| Recipient: You |
| Company: Janssen Oncology |
| Recipient: You |
| Company: Sanofi Genzyme |
| Recipient: You |
| Company: RayzeBio |
| Recipient: You |
| Company: AstraZeneca |
| Recipient: You |
| Company: Mirati Therapeutics |
| Recipient: You |
| Company: Janssen Oncology |
| Recipient: You |
| Company: Regeneron |
| Recipient: You |
| Company: Bayer |
| Recipient: You |
| Company: AstraZeneca |
| Recipient: You |
| Company: Amgen |
| Recipient: You |
| Company: Amgen |
| Recipient: You |
| Company: Sanofi |
| Recipient: You |
| Company: Takeda |
| Recipient: You |
| Company: Takeda |
| Recipient: You |
| Company: AstraZeneca |
| Recipient: You |
| Company: AstraZeneca |
| Recipient: You |
| Company: Summit Therapeutics |
| Recipient: You |
| Company: BMS GmbH & Co. KG |
| Recipient: You |
| Company: Eli Lily |
| Recipient: You |
| Company: Regeneron |
| Recipient: You |
| Company: Bayer |
| Recipient: You |
| Company: Regeneron |
| Recipient: You |
| Company: AstraZeneca |
| Recipient: You |
| Company: IDEOlogy Health |
| Recipient: You |
| Company: Natera Oncology |
| Recipient: You |
| Company: Daichi Sankyo |
| Recipient: You |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: Bioalta |
| Recipient: Your Institution |
| Company: Takeda |
| Recipient: Your Institution |
| Company: Amgen |
| Recipient: Your Institution |
| Company: Novartis/Ipsen |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| No Relationships to Disclose |
|
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| Company: Regeneron |
| Recipient: You |
|
| Other Relationship |
| Company: OncLive/MJH Life Sciences |
| Recipient: You |
| Company: NIH/NCI |
| Recipient: You |
|
| (OPTIONAL) Uncompensated Relationships |
| not answered |
|
|
| (OPTIONAL) Open Payments Link |
| not answered |
|
|